{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059136","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.690028+00:00","generated_at":"2026-06-02T06:28:38.825040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data","bullets":["Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.","Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.","Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.","GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.","EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059136","json":"https://secwatch.observer/filing/0001104659-24-059136.json","markdown":"https://secwatch.observer/filing/0001104659-24-059136.md","text":"https://secwatch.observer/filing/0001104659-24-059136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/0001104659-24-059136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/tm2413446d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:28:38.825040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5e3c5737173875f3d3a0b358f014026217fb450","claim":"Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/0001104659-24-059136-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}